Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Common Equity: 2014-2024

Historic Common Equity for KalVista Pharmaceuticals (KALV) over the last 6 years, with Dec 2024 value amounting to $164.4 million.

  • KalVista Pharmaceuticals' Common Equity was N/A to $164.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $164.4 million, marking a year-over-year change of. This contributed to the annual value of $206.6 million for FY2024, which is N/A change from last year.
  • Latest data reveals that KalVista Pharmaceuticals reported Common Equity of $164.4 million as of Q4 2024, which was up 22.66% from $134.0 million recorded in Q4 2024.
  • Over the past 5 years, KalVista Pharmaceuticals' Common Equity peaked at $206.6 million during Q2 2024, and registered a low of $58.6 million during Q1 2021.
  • Moreover, its 2-year median value for Common Equity was $139.3 million (2023), whereas its average is $145.7 million.
  • Per our database at Business Quant, KalVista Pharmaceuticals' Common Equity crashed by 34.74% in 2021 and then climbed by 24.02% in 2024.
  • Quarterly analysis of 4 years shows KalVista Pharmaceuticals' Common Equity stood at $65.0 million in 2020, then slumped by 34.74% to $58.6 million in 2021, then reached $114.4 million in 2023, then increased by 17.08% to $164.4 million in 2024.
  • Its Common Equity stands at $164.4 million for Q4 2024, versus $134.0 million for Q4 2024 and $172.8 million for Q3 2024.